AR102966A1 - ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO M DEL VIRUS METAPNEUMOVIRUS HUMANO (hMPV), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR hMPV - Google Patents
ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO M DEL VIRUS METAPNEUMOVIRUS HUMANO (hMPV), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR hMPVInfo
- Publication number
- AR102966A1 AR102966A1 ARP150104031A ARP150104031A AR102966A1 AR 102966 A1 AR102966 A1 AR 102966A1 AR P150104031 A ARP150104031 A AR P150104031A AR P150104031 A ARP150104031 A AR P150104031A AR 102966 A1 AR102966 A1 AR 102966A1
- Authority
- AR
- Argentina
- Prior art keywords
- hmpv
- seq
- human metapneumovirus
- antigen
- identity
- Prior art date
Links
- 241000342334 Human metapneumovirus Species 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 230000001413 cellular effect Effects 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 3
- 101710085938 Matrix protein Proteins 0.000 abstract 2
- 101710127721 Membrane protein Proteins 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 239000012472 biological sample Substances 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 230000000241 respiratory effect Effects 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Reivindicación 1: Anticuerpo monoclonal o un fragmento de él que se une a la proteína M del virus respiratorio Metapneumovirus humano (hMPV) caracterizado porque comprende una región variable de la cadena pesada que tiene una secuencia con al menos un 90%, 95% o 99%, de identidad con la SEQ ID Nº 1 o SEQ ID Nº 5 y una región variable de la cadena liviana que tiene una secuencia con al menos un 90%, 95% o 99% de identidad con la SEQ ID Nº 2 o SEQ ID Nº 6. Reivindicación 3: Conjunto de secuencias nucleotídicas que codifican un anticuerpo monoclonal o un fragmento de él que se une a la proteína M del virus respiratorio Metapneumovirus humano (hMPV) de acuerdo a la reivindicación 1 ó 2, caracterizado porque comprende una secuencia nucleotídica con al menos un 80%, 85%, 90%, 95% y 99% de identidad con la SEQ ID Nº 3, o la SEQ ID Nº 7 y sus reversos complementarios, que codifica la región variable de la cadena pesada del anticuerpo y comprende una secuencia nucleotídica con al menos un 80%, 85%, 90%, 95% y 99% de identidad con la SEQ ID Nº 4 o la SEQ ID Nº 8 y sus reversos complementarios, que codifican la región variable de la cadena liviana del anticuerpo. Reivindicación 4: Método in vitro y/o ex-vivo de diagnóstico de infección por hMPV en una muestra biológica, caracterizado porque el método comprende poner en contacto la muestra biológica con el anticuerpo monoclonal contra hMPV o un fragmento de él de acuerdo a la reivindicación 1 ó 2 y detectar la unión del anticuerpo con el antígeno. Reivindicación 9: Kit de diagnóstico para detectar hMPV, caracterizado porque comprende al anticuerpo monoclonal contra hMPV de acuerdo a la reivindicación 1 ó 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2014003373A CL2014003373A1 (es) | 2014-12-11 | 2014-12-11 | Anticuerpos monoclonales especificos para el antígeno m del virus metapneumovirus humano (hmpv), producidos y secretados por hibridomas celulares , útiles para la deteccion y el diagnostico de la infeccion causada por hmpv. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102966A1 true AR102966A1 (es) | 2017-04-05 |
Family
ID=53404103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150104031A AR102966A1 (es) | 2014-12-11 | 2015-12-10 | ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO M DEL VIRUS METAPNEUMOVIRUS HUMANO (hMPV), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR hMPV |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9995747B2 (es) |
| EP (2) | EP3495386A1 (es) |
| KR (1) | KR102339334B1 (es) |
| CN (1) | CN107207584B (es) |
| AR (1) | AR102966A1 (es) |
| BR (1) | BR112017012511B1 (es) |
| CA (2) | CA2970482A1 (es) |
| CL (1) | CL2014003373A1 (es) |
| CO (1) | CO2017005781A2 (es) |
| DE (1) | DE112015005539T5 (es) |
| GB (2) | GB2547603B (es) |
| MX (1) | MX2017007611A (es) |
| PE (1) | PE20171734A1 (es) |
| RU (1) | RU2698052C2 (es) |
| UY (1) | UY36431A (es) |
| WO (1) | WO2016092380A1 (es) |
| ZA (2) | ZA201704530B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3111336A1 (en) * | 2018-09-03 | 2020-03-12 | Pontificia Universidad Catolica De Chile | Specific monoclonal antibody against the n antigen of human respiratory syncytial virus (hrsv) useful for treating infection, detection thereof and diagnosis |
| JP7274904B2 (ja) * | 2019-03-26 | 2023-05-17 | 田中貴金属工業株式会社 | ヒトメタニューモウイルス検出用試薬 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8715922B2 (en) * | 2001-01-19 | 2014-05-06 | ViroNovative | Virus causing respiratory tract illness in susceptible mammals |
| CA2523319A1 (en) * | 2003-04-25 | 2004-11-11 | Medimmune Vaccines, Inc. | Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus |
| EP1473037A1 (en) * | 2003-05-02 | 2004-11-03 | Vironovative B.V. | Treatment of hPMV infections with Ribavirin |
| US20060216700A1 (en) * | 2005-03-10 | 2006-09-28 | Medimmune Vaccines, Inc. | Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus |
| CA2624291A1 (en) * | 2005-10-03 | 2007-04-12 | Seneca College Of Applied Arts & Technology | Nucleic acid immunological composition for human metapneumovirus |
| US8492097B2 (en) * | 2006-04-24 | 2013-07-23 | Diagnostic Hybrids, Inc. | Compositions and methods for human metapneumovirus monoclonal antibodies |
| EP2084185A4 (en) * | 2006-10-04 | 2010-11-17 | Scripps Research Inst | HUMAN ANTIBODIES THAT NEUTRALIZE HUMAN METAPNEUMOVIRUS |
| WO2008148170A1 (en) * | 2007-06-08 | 2008-12-11 | The University Of Queensland | Human metapneumovirus immunogenic peptides, compositions, and methods of use |
| CN102145167A (zh) * | 2010-02-05 | 2011-08-10 | 重庆医科大学附属儿童医院 | 重组人类偏肺病毒疫苗 |
| CL2011003002A1 (es) * | 2011-11-25 | 2012-05-25 | Univ Pontificia Catolica Chile | Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento. |
-
2014
- 2014-12-11 CL CL2014003373A patent/CL2014003373A1/es unknown
-
2015
- 2015-02-02 RU RU2017120228A patent/RU2698052C2/ru active
- 2015-02-02 PE PE2017000986A patent/PE20171734A1/es unknown
- 2015-02-02 WO PCT/IB2015/050790 patent/WO2016092380A1/es active Application Filing
- 2015-02-02 CN CN201580073977.9A patent/CN107207584B/zh active Active
- 2015-02-02 MX MX2017007611A patent/MX2017007611A/es unknown
- 2015-02-02 EP EP18188183.0A patent/EP3495386A1/en active Pending
- 2015-02-02 EP EP15866549.7A patent/EP3231815A4/en active Pending
- 2015-02-02 US US15/535,170 patent/US9995747B2/en active Active
- 2015-02-02 DE DE112015005539.8T patent/DE112015005539T5/de active Pending
- 2015-02-02 CA CA2970482A patent/CA2970482A1/en not_active Abandoned
- 2015-02-02 CA CA3168348A patent/CA3168348A1/en active Pending
- 2015-02-02 GB GB1709129.9A patent/GB2547603B/en active Active
- 2015-02-02 KR KR1020177019261A patent/KR102339334B1/ko active IP Right Grant
- 2015-02-02 BR BR112017012511-0A patent/BR112017012511B1/pt active IP Right Grant
- 2015-02-02 GB GB1901874.6A patent/GB2568617A/en not_active Withdrawn
- 2015-12-10 AR ARP150104031A patent/AR102966A1/es unknown
- 2015-12-11 UY UY0001036431A patent/UY36431A/es unknown
-
2017
- 2017-06-12 CO CONC2017/0005781A patent/CO2017005781A2/es unknown
- 2017-07-04 ZA ZA2017/04530A patent/ZA201704530B/en unknown
-
2018
- 2018-07-09 ZA ZA2018/04550A patent/ZA201804550B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017007611A (es) | 2017-09-18 |
| UY36431A (es) | 2016-01-29 |
| CA3168348A1 (en) | 2016-06-16 |
| GB2547603B (en) | 2019-10-30 |
| RU2017120228A3 (es) | 2019-01-11 |
| EP3231815A1 (en) | 2017-10-18 |
| CL2014003373A1 (es) | 2015-04-10 |
| BR112017012511A2 (pt) | 2018-02-27 |
| KR20170086668A (ko) | 2017-07-26 |
| RU2017120228A (ru) | 2019-01-11 |
| EP3231815A4 (en) | 2018-02-21 |
| ZA201804550B (en) | 2019-09-25 |
| PE20171734A1 (es) | 2017-12-04 |
| KR102339334B1 (ko) | 2021-12-14 |
| GB201901874D0 (en) | 2019-04-03 |
| GB2547603A (en) | 2017-08-23 |
| RU2698052C2 (ru) | 2019-08-21 |
| US9995747B2 (en) | 2018-06-12 |
| WO2016092380A1 (es) | 2016-06-16 |
| CO2017005781A2 (es) | 2017-08-31 |
| CN107207584A (zh) | 2017-09-26 |
| CN107207584B (zh) | 2021-01-08 |
| ZA201704530B (en) | 2018-11-28 |
| CA2970482A1 (en) | 2016-06-16 |
| GB2568617A (en) | 2019-05-22 |
| BR112017012511B1 (pt) | 2023-12-12 |
| DE112015005539T5 (de) | 2017-08-31 |
| US20170343546A1 (en) | 2017-11-30 |
| GB201709129D0 (en) | 2017-07-26 |
| EP3495386A1 (en) | 2019-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002105A1 (es) | Método in vitro para determinar un pronóstico pobre en un paciente que tiene melanoma que comprende: (a) detectar el nivel de expresión de un ligando similar a delta 3 (dll3) en una muestra, donde la detección comprende poner en contacto la muestra con un anticuerpo anti-dll3. | |
| CY1121900T1 (el) | Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 | |
| AR098126A1 (es) | Anticuerpos anti-ly6e (locus e del complejo del antígeno 6 linfocítico), inmunoconjugados y métodos para usarlos | |
| AR084210A1 (es) | PROTEINAS DE UNION AL TNF-a | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
| AR106188A1 (es) | Anticuerpos anti-cd19 humano humanizados y métodos de utilización | |
| PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
| BR112018015754A2 (pt) | anticorpos anti-tnf, composições, métodos e uso para o tratamento ou prevenção de diabetes tipo 1 | |
| CO6362024A2 (es) | Anticuerpos humanos de alta afinidad para el receptor il-4 humano | |
| BR112016024515A2 (pt) | proteínas do agonista do receptor trail de cadeia única | |
| CO6700829A2 (es) | Moduladores novedosos y métodos de uso | |
| PH12015502849A1 (en) | Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers | |
| EA201690213A1 (ru) | Композиции и способ лечения связанных с комплементом состояний | |
| PE20220004A1 (es) | Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh | |
| EA201391011A1 (ru) | Мономерные и мультимерные иммуногенные пептиды | |
| MX353464B (es) | Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles. | |
| WO2015112558A3 (en) | Peptides, devices, and methods for the detection of anaplasma antibodies | |
| CY1119873T1 (el) | Βελτιωμενα διαγνωστικα εμβολιου | |
| AR107440A1 (es) | ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO pIII DE ADENOVIRUS HUMANO (ADV), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR ADV | |
| EP4300101A3 (en) | Antigenic peptides and uses thereof for diagnosing and treating autism | |
| AR102966A1 (es) | ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO M DEL VIRUS METAPNEUMOVIRUS HUMANO (hMPV), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR hMPV | |
| MX2021007871A (es) | Anticuerpos monoclonales especificos para el antigeno pb2 del virus de la influenza humana (flu), secuencias nucleotidicas; metodo y kit de diagnostico de infeccion producida por flu. | |
| BR112018068637A2 (pt) | podocalixina e anticorpo relacionado a tra, métodos de preparação e usos como agente terapêutico anticancerígeno | |
| GB2541596A (en) | Method and composition for determining specific antibody responses to species of filovirus |